Skip to Content

CAVATAK and Pancreatic Cancer Preclinical Research Presentation

Sydney, Feb. 11, 2011--Viralytics Limited (ASX: VLA, OTC: VRACY) is pleased to announce that a paper investigating the oncolytic activity of CAVATAKTM in human pancreatic cancer cells has been accepted for presentation at the up coming 6th International Conference on Oncolytic Viruses as Cancer Therapeutics, March 16-19, 2011 in Las Vegas, USA.

The paper entitled “Oncolytic activity of Coxsackievirus A21 (CAVATAKTM) in human pancreatic cancer” will be presented by Dr Gough Au from the School of BioMedical Sciences and Pharmacy, the University of Newcastle. Following presentation of the above paper, it will be made available on the Viralytics website.

“Preliminary studies have indicated that a high proportion of human pancreatic cancers express elevated levels of surface ICAM-1. CAVATAKTM uses the ICAM-1 receptor to invade and destroy cancerous cells. As such these findings earmark pancreatic cancer as an indication that warrants further investigation in CAVATAKTM studies. Initial animal pancreatic tumour studies are now underway” said Dr Darren Shafren, Viralytics Chief Scientific Officer.
The relative expression of ICAM-1 in both normal and cancerous human pancreatic is shown in the picture below. The first line of pictures display normal human pancreatic tissues, while the second line shows human pancreatic cancer tissue. The brown cellular staining surrounding the black arrow heads indicates high levels of surface ICAM-1.

Level 2 55 Grandview St Pymble Sydney NSW 2073 Australia
T +61 2 99884000: F +61 2 99880999 :

The current research on human pancreatic cancer strengthens Viralytics? pipeline of pre-clinical research using CAVATAKTM in multiple myeloma, lung, bladder and primary brain cancers.

The incidence of pancreatic cancer has increased during the past several decades and ranks as the fourth leading cause of cancer death in the United States. In 2010, the estimated number of new cases and deaths from pancreatic cancer in the United States is 43,150 and 36,800, respectively. Pancreatic cancer has the highest mortality rate of all major cancers with 94% of patients dying within five years of initial diagnosis. 75% of patients die within the first year of diagnosis with only 6% surviving more than five years.

Viralytics currently has a Phase II Investigational New Drug application for late stage melanoma patients under discussion with the US Food and Drug Administration using its lead oncolytic virus, CAVATAKTM (Coxsackievirus A21). The company is also completing two Phase I safety trials in Australia, studying the safety of both intratumoural and intravenous delivery of CAVATAKTM.

Bryan Dulhunty
Managing Director
T: 02 9988 4000

About Viralytics Ltd: Viralytics is listed on the Australian Stock Exchange (ASX code: VLA), Viralytics ADR trades under VRACY on the OTC market in the USA. Viralytics? principal asset is the intellectual property relating to CAVATAKTM, an Oncolytic Virus technology. CAVATAKTM is the trade name for Viralytics? proprietary formulation of the Coxsackievirus Type A21 (CVA21). CVA21 is a human virus that occurs naturally in the community. CVA21 has been associated with upper respiratory infection ( “cold” like symptoms) and is self limiting, requiring no specific treatment for those infected to completely recover. In order to infect a cell, CVA21 must first attach to the outside of a cell, using a specific „receptor? on the cell?s surface (like a key fitting a lock). CVA21 uses two receptors to infect cells, intercellular adhesion molecule-1 (ICAM-1) and/or decay accelerating factor (DAF). Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types, including: melanoma, prostate cancer, breast cancer, multiple myeloma and others.

Level 2 55 Grandview St Pymble Sydney NSW 2073 Australia
T +61 2 99884000: F +61 2 99880999 :

Posted: February 2011